Explorative Phase-II-Plattformstudie zu Volrustomig-Priming-Regimen (eVOLVE-01)
Eine offene Phase-II-Studie zur Bewertung der Sicherheit, Verträglichkeit, Pharmakokinetik, Immunogenität und Antitumoraktivität von Volrustomig-Priming-Therapien in Kombination mit anderen Antikrebsmitteln bei Teilnehmern mit soliden Tumoren (eVOLVE-01)
Purpose of this study is to assess the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of volrustomig in combination with other anticancer drugs in participants with specified solid tumors.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
This Phase II, platform, open-label, multicenter study will evaluate the efficacy, safety, and tolerability of volrustomig in combination with anticancer drugs in various solid tumor types.
This platform study currently includes 2 substudies:
Substudy 1: metastatic non-small cell lung cancer (mNSCLC) (non-squamous [NSQ]). Participants will be randomized in two treatment arms: Arm 1A and Arm 1B.
Substudy 2: mNSCLC (squamous [SQ] or NSQ). Participants will enroll to the Arm 2A only.
All arms will test a volrustomig dosing in combination with chemotherapy.
Studientyp
Studientyp
Einschreibung (Tatsächlich)
Einschreibung
Phase
Phase
- Phase 2
Kontakte und Standorte
Studienorte
-
-
-
Beijing, China, 100730
- Research Site
-
Hangzhou, China, 310014
- Research Site
-
Jinan, China, 250013
- Research Site
-
Yantai, China, 264000
- Research Site
-
Zhengzhou, China, 450000
- Research Site
-
-
-
-
-
Bois-Guillaume, Frankreich, 76031
- Research Site
-
Caen, Frankreich, 14076
- Research Site
-
Dijon, Frankreich, 21079
- Research Site
-
Montpellier, Frankreich, 34070
- Research Site
-
-
-
-
-
Batumi, Georgia, 6010
- Research Site
-
Tbilisi, Georgia, 0144
- Research Site
-
Tbilisi, Georgia, 0112
- Research Site
-
Tbilisi, Georgia, '0159
- Research Site
-
Tbilisi, Georgia, 186
- Research Site
-
Tbilisi, Georgia, 0114
- Research Site
-
-
-
-
-
Athens, Griechenland, 115 27
- Research Site
-
Athens, Griechenland, 12462
- Research Site
-
Elaiones, Griechenland, 546 23
- Research Site
-
Piraeus, Griechenland, 185 47
- Research Site
-
Thessaloniki, Griechenland, 57001
- Research Site
-
-
-
-
-
Genoa, Italien, 16132
- Research Site
-
Meldola, Italien, 47014
- Research Site
-
Milan, Italien, 20133
- Research Site
-
Naples, Italien, 80131
- Research Site
-
Orbassano, Italien, 10043
- Research Site
-
Perugia, Italien, 06132
- Research Site
-
Rozzano, Italien, 20089
- Research Site
-
Udine, Italien, 33100
- Research Site
-
Verona, Italien, 37134
- Research Site
-
-
-
-
-
Kuala Lumpur, Malaysia, 59100
- Research Site
-
Kuching, Malaysia, 93586
- Research Site
-
Perai, Malaysia, 13700
- Research Site
-
-
-
-
-
Lisbon, Portugal, 1649-035
- Research Site
-
Lisbon, Portugal, 1169-050
- Research Site
-
Lisbon, Portugal, 1400-038
- Research Site
-
Porto, Portugal, 4099-001
- Research Site
-
-
-
-
-
Cluj-Napoca, Rumänien, 400641
- Research Site
-
Craiova, Rumänien, 200542
- Research Site
-
Floreşti, Rumänien, 407280
- Research Site
-
-
-
-
-
Geneva, Schweiz, 1205
- Research Site
-
Lausanne, Schweiz, 1011
- Research Site
-
Winterthur, Schweiz, 8401
- Research Site
-
Zurich, Schweiz, 8091
- Research Site
-
-
-
-
-
Belgrade, Serbien, 11000
- Research Site
-
-
-
-
-
A Coruña, Spanien, 15009
- Research Site
-
Alcorcón, Spanien, 28922
- Research Site
-
Barcelona, Spanien, 08041
- Research Site
-
Madrid, Spanien, 28041
- Research Site
-
Málaga, Spanien, 29004
- Research Site
-
Pamplona, Spanien, 31008
- Research Site
-
Santander, Spanien, 39008
- Research Site
-
Santiago de Compostela, Spanien, 15706
- Research Site
-
Valencia, Spanien, 46026
- Research Site
-
Valencia, Spanien, 46015
- Research Site
-
-
-
-
-
Seongnam, Südkorea, 13620
- Research Site
-
Seoul, Südkorea, 03722
- Research Site
-
Suwon, Südkorea, 16247
- Research Site
-
-
-
-
-
Changhua, Taiwan, 50006
- Research Site
-
New Taipei City, Taiwan, 23561
- Research Site
-
Taipei, Taiwan, 106
- Research Site
-
Taipei, Taiwan, 110
- Research Site
-
-
-
-
California
-
Los Angeles, California, Vereinigte Staaten, 90067
- Research Site
-
-
North Carolina
-
Chapel Hill, North Carolina, Vereinigte Staaten, 27514
- Research Site
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Key Inclusion Criteria:
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 with no deterioration.
- Life expectancy greater than or equal to (>=) 12 weeks.
- Adequate organ and bone marrow function.
- Body weight greater than (>) 35 kilograms (kg) at screening and at randomization.
- Histologically or cytologically documented NSQ NSCLC in substudy 1 and SQ or NSQ mNSCLC in substudy 2.
- Absence of sensitizing epidermal growth factor receptor (EGFR) mutations.
- Absence of documented tumor genomic alteration results from tests conducted as part of standard local practice in any other actionable driver oncogenes for which there are locally approved targeted 1L therapies.
- At least one measurable lesion not previously irradiated that can be accurately measured at baseline as >= 10 millimeter (mm) in the longest diameter.
Key Exclusion Criteria:
- Spinal cord compression.
- History of primary active immunodeficiency.
- Active or prior documented autoimmune or inflammatory disorders.
- Mixed small-cell lung cancer and NSCLC histology or sarcomatoid variant.
- Brain metastases unless asymptomatic, stable, and not requiring steroids for at least 14 days prior to start of study intervention. A minimum of 2 weeks must have elapsed between the end of radiation therapy and study enrollment.
- Prior chemotherapy or any other systemic therapy for Stage IV NSCLC. Participants who have received prior platinum-containing adjuvant, neoadjuvant, or definitive chemoradiation for local disease are eligible, provided that progression has occurred greater (>) 12 months from end of last therapy.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Substudy 1: Arm 1A: Volrustomig dose regimen 1 + Carboplatin and Pemetrexed
Volrustomig priming dose followed by volrustomig dosing regimen 1 in combination with carboplatin and pemetrexed. |
Participants will receive volrustomig via intravenous (IV) infusion.
Andere Namen:
Participants will receive carboplatin via IV infusion. Participants will receive pemetrexed via IV infusion. |
|
Experimental: Substudy 1: Arm 1B: Volrustomig dose regimen 2 + Carboplatin and Pemetrexed
Volrustomig priming dose followed by volrustomig dosing regimen 2 in combination with carboplatin and pemetrexed. |
Participants will receive volrustomig via intravenous (IV) infusion.
Andere Namen:
Participants will receive carboplatin via IV infusion. Participants will receive pemetrexed via IV infusion. |
|
Experimental: Substudy 2: Arm 2A: Volrustomig dose regimen 2 +Ramucirumab + Carboplatin + Pemetrexed or Paclitaxel
Volrustomig priming dose followed by volrustomig dosing regimen 2 in combination with ramucirumab and histology-specific chemotherapy (carboplatin+ either pemetrexed or paclitaxel). |
Participants will receive volrustomig via intravenous (IV) infusion.
Andere Namen:
Participants will receive carboplatin via IV infusion. Participants will receive pemetrexed via IV infusion. Participants will receive ramucirumab via IV infusion. Participants will receive paclitaxel via IV infusion. |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Zeitfenster: From screening (Days -28 to Day -1) up to 2 year 10 months
|
The safety and tolerability of volrustomig in combination with other anticancer drugs in participants with specified solid tumors will be assessed. |
From screening (Days -28 to Day -1) up to 2 year 10 months
|
|
Confirmed Objective Response rate (ORR)
Zeitfenster: Up to 2 year 10 months
|
ORR is defined as the percentage of participants who have a confirmed complete response (CR) or confirmed partial response (PR), as per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1). |
Up to 2 year 10 months
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Disease Control Rate (DCR)
Zeitfenster: Up to 2 year 10 months
|
DCR is defined as the percentage of participants who have a CR or PR or who have stable disease (SD) after the date of randomization or first dose. |
Up to 2 year 10 months
|
|
Duration of Response (DOR)
Zeitfenster: Up to 2 year 10 months
|
DOR is defined as the time from the date of first documented response until the date of documented progression or death due to any cause (in the absence of progression). |
Up to 2 year 10 months
|
|
Progression Free Survival (PFS)
Zeitfenster: Up to 2 year 10 months
|
PFS is defined as the time from randomization or first dose until radiological progression or death due to any cause (in the absence of progression). |
Up to 2 year 10 months
|
|
Overall Survival (OS)
Zeitfenster: Up to 2 year 10 months
|
OS is defined as the time from randomization or first dose until the date of death due to any cause. |
Up to 2 year 10 months
|
|
Serum Concentration of Volrustomig
Zeitfenster: Up to 2 year 10 months
|
The serum concentrations volrustomig alone and when used in combination with other anticancer agents in participants with pre-specified solid tumors will be assessed. |
Up to 2 year 10 months
|
|
Trough concentration (Ctrough)
Zeitfenster: Up to 2 year 10 months
|
The trough concentrations volrustomig alone and when used in combination with other anticancer agents in participants with pre-specified solid tumors will be assessed. |
Up to 2 year 10 months
|
|
Maximum Observed Concentration (Cmax)
Zeitfenster: Up to 2 year 10 months
|
The serum concentrations volrustomig alone and when used in combination with other anticancer agents in participants with pre-specified solid tumors will be assessed. |
Up to 2 year 10 months
|
|
Area Under the Curve (AUC)
Zeitfenster: Up to 2 year 10 months
|
The AUC concentrations of volrustomig alone and when used in combination with other anticancer agents in participants with pre-specified solid tumors will be assessed. |
Up to 2 year 10 months
|
|
Number of Participants with Positive Antidrug Antibodies (ADAs)
Zeitfenster: Up to 2 year 10 months
|
The incidence of ADAs against volrustomig or other anticancer agents in serum will be assessed. |
Up to 2 year 10 months
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Neubildungen nach Standort
- Neubildungen
- Erkrankungen der Atemwege
- Lungenkrankheit
- Neubildungen der Atemwege
- Thoraxneoplasmen
- Lungentumoren
- Karzinom, bronchogen
- Bronchiale Neubildungen
- Karzinom, nicht-kleinzellige Lunge
- Aminosäuren, Peptide und Proteine
- Proteine
- Organische Chemikalien
- Heterocyclische Verbindungen
- Heterocyclische Verbindungen, 2-Ring
- Heterocyclische Verbindungen, Fusionsring
- Kohlenwasserstoffe
- Cycloparaffine
- Kohlenwasserstoffe, alicyclisch
- Kohlenwasserstoffe, zyklisch
- Terpene
- Antikörper, monoklonal, humanisiert
- Antikörper, monoklonal
- Antikörper
- Immunglobuline
- Immunoproteine
- Blutproteine
- Serumglobuline
- Globuline
- Koordinationskomplexe
- Guanine
- Hypoxanthen
- Purinonen
- Purines
- Glutamaten
- Aminosäuren, saur
- Aminosäuren
- Aminosäuren, Dicarboxylic
- Taxoid
- Cyclodececane
- Diterpene
- Pemetrexed
- Ramucirumab
- Carboplatin
- Paclitaxel
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- D798KC00001
- 2023-509482-20-00 (Registrierungskennung: CTIS)
- 2023 (US NIH Stipendium/Vertrag)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Qualified researchers can request access to anonymized individual patient-leveldata from AstraZeneca group of companies sponsored clinical trials via therequest portal Vivli.org. All requests will be evaluated as per the AZ disclosurecommitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure."Yes",indicates that AZ are accepting requests for IPD, but this does not mean allrequests will be approved.
IPD-Sharing-Zeitrahmen
AstraZeneca will meet or exceed data availability as per the commitment smade to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment athttps://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD-Sharing-Zugriffskriterien
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure researchenvironmentVivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Art der unterstützenden IPD-Freigabeinformationen
- STUDIENPROTOKOLL
- SAFT
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .